Plain-English translation of NCT04437654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a blood thinner called apixaban can help prevent strokes in people with atrial fibrillation (an irregular heartbeat condition) who have a moderate stroke risk. About half of participants will take the medication twice daily for 2 years, while the other half will receive standard care without this blood thinner. Researchers will track whether this treatment reduces strokes and other serious heart events while monitoring for any bleeding risks.
Atrial fibrillation increases stroke risk, but doctors aren't sure whether people with moderate stroke risk always need blood thinners, since the benefit must be weighed against the risk of bleeding. This study will help clarify whether this medication is safe and effective enough to recommend for patients in this middle-risk category.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either take apixaban (a blood thinner pill) twice daily or receive your usual care without this medication for 2 years. Throughout the study, you'll have regular check-ins to monitor your health, answer questions about your quality of life and thinking, and watch for any signs of bleeding or stroke. The researchers will track heart-related events, hospitalizations, and how well you're doing overall to see whether the medication helps prevent strokes safely.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
South Korea